For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Search Close Search
Search Close Search

Supporting the boldest research ideas in the interdisciplinary labs under the direction of Robert H. Brown Jr., DPhil, MD, one of the world's foremost authorities on ALS.

Boston Marathon 2023

This year's event will take place on Monday, April 17, 2023, and the Cellucci Fund is looking for marathon runners!

The UMass ALS Cellucci Fund is now accepting applications for charity runners who commit to raising at least $7,500 each for ALS research at UMass Chan Medical School. We are also able to accept qualified and registered runners as additional team members with no minimum fundraising requirement.

The application deadline is Dec. 16, 2022. 

Submit your application


 marathon generic 200H.png

SPONSOR the Boston Marathon 2022 Cellucci Fund Team

Your organization can provide hope to those affected by ALS with something very rare and very needed: Hope. Your organization can sponsor this year's team in their fundraising efforts.

 brown-watts-crop.jpg

UMass Chan clinical trial shows antisense oligonucleotide safely suppresses mutant ALS gene in pilot human study

Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan Medical School, Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of the ALS (amyotrophic lateral sclerosis) gene known as C9ORF72 in a single-patient pilot study. C9ORF72 is the most common cause of familial ALS and familial frontotemporal dementia (FTD). The results, published in Nature Medicine, have the potential to catalyze research into treatments for ALS, FTD and other neurodegenerative diseases.

Read more
Page Menu